Frontier Pharma: Type 2 Diabetes Mellitus

NEW YORK, August 9, 2018 /PRNewswire/ — Frontier Pharma: Type 2 Diabetes Mellitus – Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease

Read the full report: https://www.reportlinker.com/p05385770

Summary

Type 2 diabetes mellitus (T2DM) is a major metabolic disease and one of the leading causes of death worldwide. The prevalence is on the rise, alongside increases in obesity due to lifestyle changes in the 21st century. Type 2 diabetes is characterized by insulin resistance leading to dysregulation of glucose control and chronic hyperglycemia.

This leads to several co-morbidities and complications, some of which are associated with damage to blood vessels as a result of elevated blood glucose levels. The disease is progressive: patients’ standard of living deteriorate over time and the symptoms worsen, meaning more complex treatment regimens are required over time. The complexity of the treatment means there is a high diversity of marketed products. In recent years new drug types have been great commercial successes and reached blockbuster status. This alongside the financial cost of type 2 diabetes to healthcare providers has led to significant investment in R&D on therapeutics in this area.

The demand for T2DM therapeutics has resulted in a large and competitive market landscape, with a number of drugs competing with one another for different market segments, across multiple lines of therapy. Since the mid-2000s a number of new drug classes have entered the market including glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose linked transporter-2 (SGLT-2) inhibitors. These drug classes have proved to be highly commercially successful.

The T2DM pipeline is large with more than 560 products in active development, which accounts for almost a third of the metabolic disorders pipeline. This pipeline is dominated by products acting on G protein coupled receptors (GPCR) and protein kinases.

First-in-class products have the greatest potential in terms of development and commercial prospects. Among the pipeline products, 152 are first-in-class, which act on 95 distinct first-in-class targets. In line with the overall pipeline, first-in-class innovation is dominated by products acting on GPCRS and protein kinases. Additionally, there is a strong representation of first-in-class products at the Preclinical development stage.

The report “Frontier Pharma: Type 2 Diabetes Mellitus – Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease” enables you to –

– Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, and diagnosis and treatment options.

– Identify leading products and key unmet needs within the market.

Leave a Reply

Your email address will not be published. Required fields are marked *